Financial News Agency, November 27 (Reporter Zhang Chenjing) With intensive support policies and strong market demand, computing power leasing has become a “cross-border code”. Compared with condiments in the main business, investors are paying more attention to the current transformation progress of Lotus Health (600186.SH). At the performance briefing held by the company today, investors frequently asked questions about even power and prepared dishes.

Earlier, Lotus Health announced the purchase of 330 Nvidia H800 GPU series computing power servers at a total price of 693 million yuan, officially announcing the field of cross-border computing power. According to the plan, the company will procure information from Xinhua in batches. The initial purchase amount in 2023 is about 200 million yuan, and the purchase amount in 2024 is about 490 million yuan.

At today's performance briefing, investors frequently asked questions about how many computing power units were purchased in the first batch, how much computing power layout is expected to account for the company's operations, and whether it will enter semiconductors.

However, the company's management did not disclose more information and answered many times: “The company has no relevant important matters that should be disclosed that have not been disclosed.” Cao Jiasheng, president and secretary of the board of directors, told investors: “The first batch of servers purchased from Xinhua-3 has arrived, and the computing power leasing order is currently being negotiated. The computer room server was officially put into operation this year, and the operation team is already in place.”

Cross-border computing power has triggered a sharp rise in the company's stock price. Since the beginning of September, the company's stock price has climbed from a high of 3.79 yuan to 8.24 yuan/share, an increase of 1.17 times over a month. However, an old case storm 17 years ago was always shrouded in haze. In mid-October, the company received an executive ruling that put a “brake on” gains. Since then, the company's stock price has been adjusted to 6.27 yuan/share.

The matter stemmed from the 2006 loan contract dispute between the China Development Bank's Henan branch, Lotus Health, and Lotus Group. The Zhoukou Intermediate Court ruled that Lotus Health reimbursed the capital of China Development Bank Henan Branch of 995.777 million yuan, as well as interest and liquidated damages, totaling 102 million yuan. During the execution period, the two parties verbally reached a settlement agreement, and Lotus Health reimbursed CNB's Henan branch for 30 million yuan. After Lotus Health paid back 30 million yuan in 2009, the Zhoukou Intermediate Court ruled that the execution procedure for this case was terminated.

However, in March 2021, the company also received a “Notice of Resumption of Execution”. Since the applicant executioner applied for reinstatement of execution, the company became the executee. The amount involved in the case was 102 million yuan. After many reviews and rejections of applications, in November of this year, Lotus Health issued an announcement that the company once again became the executee, with an execution amount of 368.4449 million yuan.

According to the company's three-quarter report, net profit attributable to the owners of the parent company for the first three quarters was 94.5928 million yuan, and operating income was 1,614 billion yuan. It is easy to see that if the final judgment in the above case is implemented, it will have a certain impact on the company's performance.

Some investors asked about this matter: “After the company received the bank's execution letter, the stock price continued to fall and the adjustment was too large. Are there any unknown disadvantages in it?” Lotus Health did not give much explanation and once again stated, “The company has no relevant important matters that should be disclosed that have not been disclosed. Everything is subject to company announcements.”